MNOV
HEALTHCAREMediciNova Inc
AI Insight
What's Moving MNOV Today?
No stock-specific AI insight has been generated for MNOV yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.17$1.96
$1.36
Fundamentals
Market Cap$64M
P/E Ratio—
EPS$-0.23
Dividend Yield—
Dividend / Share—
ROE-26.2%
Profit Margin—
Debt / Equity—
Trading
Volume9K
Avg Volume (10D)—
Shares Outstanding49.2M
MNOV News
23 articles- Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsightYahoo Finance·Jun 8, 2026
- MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma TreatmentYahoo Finance·Jun 8, 2026
- MediciNova, Inc. Announces Completion of Last Patient Visit in Phase 2 Trial of MN-001 for Hypertriglyceridemia and NAFLD Associated with Type 2 DiabetesQuiver Quantitative·May 26, 2026
- MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)Stock Titan·May 26, 2026
- MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)GlobeNewswire Inc.·May 26, 2026
- We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business GrowthYahoo Finance·May 16, 2026
- MediciNova Inc stock (US58468P2038): Biopharma innovator targeting unmet needsAD HOC NEWS·May 12, 2026
- New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical TranslationGlobeNewswire Inc.·Apr 27, 2026
- Super Micro downgraded, MongoDB upgraded: Wall Street's top analyst callsYahoo Finance·Mar 23, 2026
- MediciNova to Participate at the 38th Annual ROTH ConferenceYahoo Finance·Mar 16, 2026
- MediciNova: Q4 Earnings SnapshotYahoo Finance·Feb 20, 2026
- Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)Yahoo Finance·Feb 19, 2026
- MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patientsYahoo Finance·Jan 29, 2026
- ATA Creativity Global Among 3 Promising Penny StocksYahoo Finance·Jan 20, 2026
- 2026 New Year’s Greetings from the CEOYahoo Finance·Jan 6, 2026
- MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral NeuropathyYahoo Finance·Dec 18, 2025
- Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsightYahoo Finance·Dec 9, 2025
- MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MNDYahoo Finance·Dec 8, 2025
- Message from the CEO to MediciNova ShareholdersYahoo Finance·Dec 1, 2025
- MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory AdvisorYahoo Finance·Nov 18, 2025
- MediciNova: Q3 Earnings SnapshotYahoo Finance·Nov 12, 2025
- MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough AwardsYahoo Finance·Nov 6, 2025
- MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)Yahoo Finance·Nov 4, 2025
All 23 articles loaded
Price Data
Open$1.36
Previous Close$1.36
Day High$1.37
Day Low$1.36
52 Week High$1.96
52 Week Low$1.17
52-Week Range
$1.17$1.96
$1.36
Fundamentals
Market Cap$64M
P/E Ratio—
EPS$-0.23
Dividend Yield—
Dividend / Share—
ROE-26.2%
Profit Margin—
Debt / Equity—
Trading
Volume9K
Avg Volume (10D)—
Shares Outstanding49.2M
About MediciNova Inc
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapies for the treatment of serious diseases with unmet medical needs in the United States. The company is headquartered in La Jolla, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—